FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Didier Cussac

Research Profile

Anatomy

CHO Cells

Living Beings

Chemicals & Drugs

Physiology

Binding, Competitive

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Agnès Auclair; Laurent Bardin; Didier Cussac; Peter Heusler; M Marien; J C Martel; A Newman-Tancredi; J A O'Connor; Marie-Bernadette Assié; Ronan Depoortère
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety.
Didier Cussac; Sophie Bernois; Claudie Cathala; Frederic FINANA; Peter Heusler; Isabelle Rauly-Lestienne; Luc De Vries
μ-opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways.
Mark J Millan; O Muller; Adrian Newman-Tancredi; Clotilde Mannoury La Cour; Philippe Marin; Valérie Audinot; Joël Bockaert; Jean A Boutin; Benjamin Chanrion; Didier Cussac; Anne Dekeyne; Benjamin Di Cara; Delphine S Dupuis; Ralf JOckers; Maud Kamal; Gilbert Lavielle
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Didier Cussac (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Agnès Auclair; Laurent Bardin; Didier Cussac; Peter Heusler; M Marien; J C Martel; A Newman-Tancredi; J A O'Connor; Marie-Bernadette Assié; Ronan Depoortère
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety.
Neuropharmacology 2013;70():338-47.
2012: Didier Cussac; Sophie Bernois; Claudie Cathala; Frederic FINANA; Peter Heusler; Isabelle Rauly-Lestienne; Luc De Vries
μ-opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways.
Cellular signalling 2012;24(8):1648-57.
2012: Mark J Millan; O Muller; Adrian Newman-Tancredi; Clotilde Mannoury La Cour; Philippe Marin; Valérie Audinot; Joël Bockaert; Jean A Boutin; Benjamin Chanrion; Didier Cussac; Anne Dekeyne; Benjamin Di Cara; Delphine S Dupuis; Ralf JOckers; Maud Kamal; Gilbert Lavielle
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
The Journal of pharmacology and experimental therapeutics 2012;340(3):750-64.
2012: Emilie Lauressergues; Zouher Majd; Bart Staels; Elodie Bert; Patrick Duriez; Dean Hum; Didier Cussac
Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation?
Neuropharmacology 2012;62(2):784-96.
2011: Peter Heusler; Stéphanie Tardif; Amélie Tourette; Liesbeth A Bruins Slot; Didier Cussac
The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D₂ and serotonin 5-HT₁A receptors.
European journal of pharmacology 2011;669(1-3):51-8.
2011: Emilie Lauressergues; Françoise Martin; Audrey Helleboid; Emmanuel Bouchaert; Didier Cussac; Régis Bordet; Dean Hum; Gérald Luc; Zouher Majd; Bart Staels; Patrick Duriez
Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.
Naunyn-Schmiedeberg's archives of pharmacology 2011;383(4):423-36.
2011: Isabelle Rauly-Lestienne; Fabrice Lestienne; Marie-Christine Ailhaud; Johan Binesse; Adrian Newman-Tancredi; Didier Cussac
Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference.
Cellular signalling 2011;23(1):58-64.
2010: Peter Heusler; Christiane Palmier; Stéphanie Tardif; Sophie Bernois; Francis C Colpaert; Didier Cussac
[(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.
Naunyn-Schmiedeberg's archives of pharmacology 2010;382(4):321-30.
2010: Peter Heusler; Isabelle Rauly-Lestienne; Amélie Tourette; Stéphanie Tardif; Marie-Christine Ailhaud; Guillaume Croville; Didier Cussac
Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist.
European journal of pharmacology 2010;640(1-3):8-14.
2010: Emilie Lauressergues; Bart Staels; Karine Valeille; Zouher Majd; Dean W Hum; Patrick Duriez; Didier Cussac
Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes.
Naunyn-Schmiedeberg's archives of pharmacology 2010;381(5):427-39.
2010: Luc De Vries; Frederic FINANA; Frédéric Cachoux; Bernard Vacher; Pierre Sokoloff; Didier Cussac
Cellular BRET assay suggests a conformational rearrangement of preformed TrkB/Shc complexes following BDNF-dependent activation.
Cellular signalling 2010;22(1):158-65.
2009: Liesbeth A Bruins Slot; Fabrice Lestienne; Catherine Grevoz-Barret; Adrian Newman-Tancredi; Didier Cussac
F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
European journal of pharmacology 2009;620(1-3):27-35.
2009: Michel Perez; Marie Lamothe; Catherine Maraval; Etienne Mirabel; Chantal Loubat; Bruno Planty; Clemens Horn; Julien Michaux; Sebastien Marrot; Robert Letienne; Christophe Pignier; Arnaud Bocquet; Florence Nadal-Wollbold; Didier Cussac; Luc de Vries; Bruno Le Grand
Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.
Journal of medicinal chemistry 2009;52(19):5826-36.
2009: Didier Cussac; Christiane Palmier; Frederic FINANA; Luc De Vries; Stéphanie Tardif; Céline Léger; Sophie Bernois; Peter Heusler
Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.
The Journal of pharmacology and experimental therapeutics 2009;331(1):222-33.
2009: Jean-Claude Martel; Marie-Bernadette Assié; Laurent Bardin; Ronan Depoortère; Didier Cussac; Adrian Newman-Tancredi
5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception.
British journal of pharmacology 2009;158(1):232-42.
2009: Jaroslava Buritova; Geraldine Berrichon; Claudie Cathala; Francis Colpaert; Didier Cussac
Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study.
Neuropharmacology 2009;56(2):350-61.
2009: Peter Heusler; Liesbeth Bruins Slot; Isabelle Rauly-Lestienne; Christiane Palmier; Stéphanie Tardif; Amélie Tourette; Marie-Christine Ailhaud; Didier Cussac
Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.
Naunyn-Schmiedeberg's archives of pharmacology 2009;379(1):87-99.
2008: Didier Cussac; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Jean-Claude Martel; Nathalie Danty; Isabelle Rauly-Lestienne
Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.
European journal of pharmacology 2008;594(1-3):32-8.
2008: Caroline Pinet; Vincent Algalarrondo; Sylvie Sablayrolles; Bruno Le Grand; Christophe Pignier; Didier Cussac; Michel Perez; Stephane N Hatem; Alain Coulombe
Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes.
Molecular pharmacology 2008;73(6):1622-31.
2008: Adrian Newman-Tancredi; Peter Heusler; Jean-Claude Martel; Anne-Marie Ormière; Nathalie Leduc; Didier Cussac
Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2008;11(3):293-307.
2008: Peter Heusler; Adrian Newman-Tancredi; Timothé Loock; Didier Cussac
Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
European journal of pharmacology 2008;581(1-2):37-46.
2008: Mark J Millan; Clotilde Mannoury La Cour; Francesca Novi; Roberto Maggio; Valérie Audinot; Adrian Newman-Tancredi; Didier Cussac; Valérie Pasteau; Jean-A Boutin; T Dubuffet; Gilbert Lavielle
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.
The Journal of pharmacology and experimental therapeutics 2008;324(2):587-99.
2007: Jean-Claude Martel; Nathalie Leduc; Anne-Marie Ormière; Valérie Faucillon; Nathalie Danty; Charlène Culie; Didier Cussac; Adrian Newman-Tancredi
WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors.
European journal of pharmacology 2007;574(1):15-9.
2007: Isabelle Rauly-Lestienne; Elisa Boutet-Robinet; Marie-Christine Ailhaud; Adrian Newman-Tancredi; Didier Cussac
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties.
Naunyn-Schmiedeberg's archives of pharmacology 2007;376(1-2):93-105.
2007: Liesbeth A Bruins Slot; Christiane Palmier; Stéphanie Tardif; Didier Cussac
Action of novel antipsychotics at human dopamine D3 receptors coupled to G protein and ERK1/2 activation.
Neuropharmacology 2007;53(2):232-41.
2007: Adrian Newman-Tancredi; Didier Cussac; Ronan Depoortere
Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
Current opinion in investigational drugs (London, England : 2000) 2007;8(7):539-54.
2007: Adrian Newman-Tancredi; Marie-Bernadette Assié; Jean-Claude Martel; Cristina Cosi; L Bruins Slot; Christiane Palmier; Isabelle Rauly-Lestienne; Francis Colpaert; Bernard Vacher; Didier Cussac
F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profile.
British journal of pharmacology 2007;151(2):237-52.
2007: Peter Heusler; Adrian Newman-Tancredi; Annabelle Castro-Fernandez; Didier Cussac
Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
Neuropharmacology 2007;52(4):1106-13.
2007: Clotilde Mannoury La Cour; S Vidal; Valérie Pasteau; Didier Cussac; Mark J Millan
Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: a scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonists.
Neuropharmacology 2007;52(3):1003-14.
2007: Jean-Claude Martel; Anne-Marie Ormière; Nathalie Leduc; Marie-Bernadette Assié; Didier Cussac; Adrian Newman-Tancredi
Native rat hippocampal 5-HT1A receptors show constitutive activity.
Molecular pharmacology 2007;71(3):638-43.
2006: Luc De Vries; Christiane Palmier; Frederic FINANA; Bruno Le Grand; Michel Perez; Didier Cussac
Pharmacological characterization of protease activated receptor-1 by a serum responsive element-dependent reporter gene assay: major role of calmodulin.
Biochemical pharmacology 2006;71(10):1449-58.
2006: Liesbeth A Bruins Slot; Luc De Vries; Adrian Newman-Tancredi; Didier Cussac
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
European journal of pharmacology 2006;534(1-3):63-70.
2005: Peter Heusler; Petrus J Pauwels; Thierry Wurch; Adrian Newman-Tancredi; Jan Tytgat; Francis C Colpaert; Didier Cussac
Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling.
Neuropharmacology 2005;49(7):963-76.
2004: Mark J Millan; Laetitia Seguin; Alain Gobert; Didier Cussac; Mauricette Brocco
The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats.
Psychopharmacology 2004;174(3):341-57.
2004: Mark J Millan; Didier Cussac; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Clotilde Mannoury La Cour; Adrian Newman-Tancredi; Jean-Louis Peglion
S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
The Journal of pharmacology and experimental therapeutics 2004;309(3):903-20.
2004: Didier Cussac; Valérie Pasteau; Mark J Millan
Characterisation of Gs activation by dopamine D1 receptors using an antibody capture assay: antagonist properties of clozapine.
European journal of pharmacology 2004;485(1-3):111-7.
2003: Adrian Newman-Tancredi; Jean-Michel Rivet; Didier Cussac; Manuelle Touzard; C Chaput; Laetitia Marini; Mark J Millan
Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924.
Naunyn-Schmiedeberg's archives of pharmacology 2003;368(3):188-99.
2003: Mark J Millan; Alain Gobert; Françoise Lejeune; Anne Dekeyne; Adrian Newman-Tancredi; Valérie Pasteau; Jean-Michel Rivet; Didier Cussac
The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways.
The Journal of pharmacology and experimental therapeutics 2003;306(3):954-64.
2003: Adrian Newman-Tancredi; Didier Cussac; Laetitia Marini; Manuelle Touzard; Mark J Millan
h5-HT(1B) receptor-mediated constitutive Galphai3-protein activation in stably transfected Chinese hamster ovary cells: an antibody capture assay reveals protean efficacy of 5-HT.
British journal of pharmacology 2003;138(6):1077-84.
2002: Adrian Newman-Tancredi; Didier Cussac; Yann Quentric; Manuelle Touzard; Laurence Verrièle; Nathalie Carpentier; Mark J Millan
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):815-22.
2002: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Jean-Paul Nicolas; Frédéric De Ceuninck; Jean A Boutin; Mark J Millan
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.
The Journal of pharmacology and experimental therapeutics 2002;303(2):805-14.
2002: Mark J Millan; Lisa Maiofiss; Didier Cussac; Valérie Audinot; Jean A Boutin; Adrian Newman-Tancredi
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
The Journal of pharmacology and experimental therapeutics 2002;303(2):791-804.
2002: Adrian Newman-Tancredi; Didier Cussac; Laetitia Marini; Mark J Millan
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling.
Molecular pharmacology 2002;62(3):590-601.
2002: Didier Cussac; Adrian Newman-Tancredi; Delphine Duqueyroix; Valérie Pasteau; Mark J Millan
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
Molecular pharmacology 2002;62(3):578-89.
2002: Didier Cussac; Delphine Duqueyroix; Adrian Newman-Tancredi; Mark J Millan
Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors.
Psychopharmacology 2002;162(2):168-77.
2002: Didier Cussac; Adrian Newman-Tancredi; Yann Quentric; Nathalie Carpentier; Guillaume Poissonnet; Jean-Gilles Parmentier; Solo Goldstein; Mark J Millan
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols.
Naunyn-Schmiedeberg's archives of pharmacology 2002;365(3):242-52.
2001: Adrian Newman-Tancredi; Didier Cussac; Mauricette Brocco; Jean-Michel Rivet; C Chaput; Manuelle Touzard; Valérie Pasteau; Mark J Millan
Dopamine D2 receptor-mediated G-protein activation in rat striatum: functional autoradiography and influence of unilateral 6-hydroxydopamine lesions of the substantia nigra.
Brain research 2001;920(1-2):41-54.
2001: Valérie Audinot; Adrian Newman-Tancredi; Didier Cussac; M J Millan
Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;25(3):410-22.
2001: Mark J Millan; Adrian Newman-Tancredi; Delphine Duqueyroix; Didier Cussac
Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase.
European journal of pharmacology 2001;424(1):13-7.
2001: Mark J Millan; Adrian Newman-Tancredi; Yann Quentric; Didier Cussac
The "selective" dopamine D1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin2C receptors.
Psychopharmacology 2001;156(1):58-62.
2001: Mark J Millan; Didier Cussac; G Milligan; C Carr; Valérie Audinot; Alain Gobert; Françoise Lejeune; Jean-Michel Rivet; Mauricette Brocco; Delphine Duqueyroix; Jean-Paul Nicolas; Jean A Boutin; Adrian Newman-Tancredi
Antiparkinsonian agent piribedil displays antagonist properties at native, rat, and cloned, human alpha(2)-adrenoceptors: cellular and functional characterization.
The Journal of pharmacology and experimental therapeutics 2001;297(3):876-87.
2000: Mark J Millan; Anne Dekeyne; Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; G Milligan; Delphine Duqueyroix; Sylvie Girardon; J Mullot; Jean A Boutin; Jean-Paul Nicolas; A Renouard-Try; Jean-Michel Lacoste; Alex Cordi
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
The Journal of pharmacology and experimental therapeutics 2000;295(3):1192-205.
2000: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Françoise Lejeune; Didier Cussac; Jean-Michel Rivet; Valérie Audinot; T Dubuffet; Gilbert Lavielle
S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
The Journal of pharmacology and experimental therapeutics 2000;293(3):1048-62.
2000: Didier Cussac; Adrian Newman-Tancredi; L Sezgin; Mark J Millan
[3H]S33084: a novel, selective and potent radioligand at cloned, human dopamine D3 receptors.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):569-72.
2000: Didier Cussac; Adrian Newman-Tancredi; J P Nicolas; J A Boutin; Mark J Millan
Antagonist properties of the novel antipsychotic, S16924, at cloned, human serotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(5):549-54.
2000: Didier Cussac; Adrian Newman-Tancredi; L Sezgin; Mark J Millan
The novel antagonist, S33084, and GR218,231 interact selectively with cloned and native, rat dopamine D(3) receptors as compared with native, rat dopamine D(2) receptors.
European journal of pharmacology 2000;394(1):47-50.
2000: Mark J Millan; Alain Gobert; Jean-Michel Rivet; A Adhumeau-Auclair; Didier Cussac; Adrian Newman-Tancredi; Anne Dekeyne; Jean-Paul Nicolas; Françoise Lejeune
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.
The European journal of neuroscience 2000;12(3):1079-95.
2000: Didier Cussac; Adrian Newman-Tancredi; Yann Quentric; Mark J Millan
An innovative method for rapid characterisation of phospholipase C activity: SB242,084 competitively antagonises 5-HT2C receptor-mediated [3H]phosphatidylinositol depletion.
Naunyn-Schmiedeberg's archives of pharmacology 2000;361(2):221-3.
2000: Mark J Millan; Adrian Newman-Tancredi; Valérie Audinot; Didier Cussac; Françoise Lejeune; Jean-Paul Nicolas; Francis Cogé; Jean-Pierre Galizzi; Jean A Boutin; Jean-Michel Rivet; Anne Dekeyne; Alain Gobert
Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.
Synapse (New York, N.Y.) 2000;35(2):79-95.
2000: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Françoise Lejeune; Didier Cussac; Jean-Michel Rivet; Valérie Audinot; A Adhumeau; Mauricette Brocco; Jean-Paul Nicolas; Jean A Boutin; Nicole Despaux; Jean-Louis Peglion
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profile.
The Journal of pharmacology and experimental therapeutics 2000;292(1):38-53.
1999: Didier Cussac; Adrian Newman-Tancredi; Valérie Pasteau; Mark J Millan
Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism.
Molecular pharmacology 1999;56(5):1025-30.
1999: T Dubuffet; Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; A Loutz; Mark J Millan; Gilbert Lavielle
Novel benzopyrano[3,4-c]pyrrole derivatives as potent and selective dopamine D3 receptor antagonist.
Bioorganic & medicinal chemistry letters 1999;9(14):2059-64.
1999: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Mark J Millan
Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors.
Naunyn-Schmiedeberg's archives of pharmacology 1999;359(6):447-53.
1999: Adrian Newman-Tancredi; Didier Cussac; Valérie Audinot; Valérie Pasteau; S Gavaudan; Mark J Millan
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
Molecular pharmacology 1999;55(3):564-74.
1998: Mark J Millan; Alain Gobert; Adrian Newman-Tancredi; Valérie Audinot; Françoise Lejeune; Jean-Michel Rivet; Didier Cussac; Jean-Paul Nicolas; O Muller; Gilbert Lavielle
S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
The Journal of pharmacology and experimental therapeutics 1998;286(3):1341-55.
1993: Didier Cussac; L Caccavelli; I Pellegrini; Valérie Audinot; Philippe Jaquet; Alain Enjalbert
[Membrane receptors and coupling proteins in adenohypophyseal cells].
Comptes rendus des séances de la Société de biologie et de ses filiales 1993;187(1):14-23.
1992: L Caccavelli; Didier Cussac; I Pellegrini; Valérie Audinot; Philippe Jaquet; Alain Enjalbert
D2 dopaminergic receptors: normal and abnormal transduction mechanisms.
Hormone research 1992;38(1-2):78-83.